{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"355.3","value":"167"},{"groupId":"OG001","spread":"205.4","value":"10.9"},{"groupId":"OG002","spread":"30402.1","value":"59.4"},{"groupId":"OG003","spread":"163.5","value":"15.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"T1/2 is the half-life associated with the disposition phase slopes (alpha, beta, gamma etc.) of a semi logarithmic concentration-time curve in peripheral blood. T1/2, based on the transgene level data by qPCR, was summarized by Month 3 response, per Independent Review Committee assessment. This time frame of 60 months reflects the maximum duration up to which the transgene levels were collected to measure the half life.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG001","title":"Tisagenlecleucel - Main Cohort: SD/PD/UNK"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG002","title":"Tisagenlecleucel - Cohort A: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG003","title":"Tisagenlecleucel - Cohort A: SD/PD/UNK"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel with valid PK assessments.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Pharmacokinetics (Pk): T1/2","type":"SECONDARY","unitOfMeasure":"days"}